Currently out of the existing stock ratings of Thomas Shrader, 140 are a BUY (88.61%), 16 are a HOLD (10.13%), 2 are a SELL (1.27%).

Thomas Shrader

Work Performance Price Targets & Ratings Chart

Analyst Thomas Shrader, currently employed at BTIG, carries an average stock price target met ratio of 55.69% that have a potential upside of 49.87% achieved within 271 days.

Thomas Shrader’s has documented 296 price targets and ratings displayed on 45 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ARCT, Arcturus Therapeutics Holdings at 21-Oct-2025.

Wall Street Analyst Thomas Shrader

Analyst best performing recommendations are on VRNA (VERONA PHARMA PLC ADR).
The best stock recommendation documented was for VRNA (VERONA PHARMA PLC ADR) at 12/20/2022. The price target of $26 was fulfilled within 10 days with a profit of $7.41 (39.86%) receiving and performance score of 39.86.

Average potential price target upside

of $598 (22.23%) on ACOR (ACORDA THERAPEUTICS).
of $43.31 (45.22%) on INO (INOVIO PHARMACEUTICALS).
of $40.17 (14.98%) on BIIB (BIOGEN).

BBIO BridgeBio Pharma BCAB Bioatla BIIB Biogen CLVS Clovis Oncology ESPR Esperion Therapeutics GRTS Gritstone Oncology MNTA Momenta Pharmaceuticals PBYI Puma Biotechnology VYGR Voyager Therapeutics XON Precigen ACOR Acorda Therapeutics DNLI Denali Therapeutics NUVB Nuvation Bio INMB INmune Bio PGEN Precigen SGTX Sigilon Therapeutics ABOS Acumen Pharmaceuticals SQZ Sqz Biotechnologies Co GANX Gain Therapeutics VRNA Verona Pharma PLC ADR ALEC Alector ATHA Athira Pharma CELG Celgene MEIP MEI Pharma MGNX MacroGenics MRSN Mersana Therapeutics SELB Selecta Biosciences ANNX Annexon DTIL Precision BioSciences STOK Stoke Therapeutics BHVN Biohaven Pharmaceutical Holding Co Ltd INO Inovio Pharmaceuticals SLN Silence Therapeutics PLC PCVX Vaxcyte ACIU AC Immune Ltd ALPN Alpine Immune Sciences ANAB AnaptysBio ARCT Arcturus Therapeutics Holdings FGEN FibroGen GERN Geron HCM HUTCHMED DRC NERV Minerva Neurosciences HROW Harrow Health OVID Ovid Therapeutics RCUS Arcus Biosciences

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Raghuram Selvaraju (HC WAINWRIGHT)